Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Atypical Chronic Myeloid Leukemia

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Atypical Chronic Myeloid Leukemia in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rocca, S1
Carrà, G1
Poggio, P1
Morotti, A1
Brancaccio, M1

Reviews

1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Atypical Chronic Myeloid Leukemia

ArticleYear
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.
    Molecular cancer, 2018, 02-19, Volume: 17, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Humans; Janus Kinases; Leukemia, Myeloid, Ch

2018